Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 9/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25043852 | 1.00 | ALDH1A1 (0.60) | ALDH1A1KDM4ETAAR1HTR2CHTR2A | |
| Hydrochloric Acid SCHEMBL26110115 | 0.98 | ALDH1A1 (0.58) | ALDH1A1KDM4ETAAR1HTR2CHTR2A | |
| Hydrochloric Acid SCHEMBL29792081 | 0.98 | ALDH1A1 (0.58) | ALDH1A1KDM4ETAAR1HTR2CHTR2A | |
| Hydrochloric Acid SCHEMBL26110112 | 0.98 | ALDH1A1 (0.58) | ALDH1A1KDM4ETAAR1HTR2CHTR2A | |
| SCHEMBL25045131 | 0.90 | ALDH1A1 (0.59) | ALDH1A1KDM4ETAAR1HTR2CHTR2A | |
| SCHEMBL2966923 | 0.86 | ALDH1A1 (0.44) | ALDH1A1KDM4ETAAR1HTR2CHTR2A | |
| SCHEMBL17977106 | 0.79 | KDM4E (0.66) | ALDH1A1KDM4ETAAR1HTR6 | |
| SCHEMBL337149 | 0.75 | ALDH1A1 (1.00) | ALDH1A1KDM4E | |
| SCHEMBL14839458 | 0.75 | TAAR1 (0.50) | ALDH1A1KDM4ETAAR1HTR2CHTR2A | |
| SCHEMBL337396 | 0.75 | ALDH1A1 (1.00) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3793997-B1 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2024-03-13 | — | — | EP | claimed |
| EP-4739692-A1 | SUBSTITUTED HEXAHYDRO-2H-PYRAZINO[1,2-A]PYRAZIN-1(6H)-ONE DERIVATIVES AS ACTIVATORS OF HUMAN CASEINOLYTIC PROTEASE P (HSCLPP) | Centro Atlantico del Medicamento S.A (Ceamed, S.A) (ES) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739692-A1 | SUBSTITUTED HEXAHYDRO-2H-PYRAZINO[1,2-A]PYRAZIN-1(6H)-ONE DERIVATIVES AS ACTIVATORS OF HUMAN CASEINOLYTIC PROTEASE P (HSCLPP) | Centro Atlantico del Medicamento S.A (Ceamed, S.A) (ES) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739692-A1 | SUBSTITUTED HEXAHYDRO-2H-PYRAZINO[1,2-A]PYRAZIN-1(6H)-ONE DERIVATIVES AS ACTIVATORS OF HUMAN CASEINOLYTIC PROTEASE P (HSCLPP) | Centro Atlantico del Medicamento S.A (Ceamed, S.A) (ES) | 2026-05-13 | — | — | EP | disclosed |
| CN-115703765-B | Substituted triazole derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2025008381-A1 | SUBSTITUTED HEXAHYDRO-2H-PYRAZINO[1,2-A]PYRAZIN-1(6H)-ONE DERIVATIVES AS ACTIVATORS OF HUMAN CASEINOLYTIC PROTEASE P (HSCLPP) | CENTRO ATLÁNTICO DEL MEDICAMENTO, S.A. (CEAMED S.A.) (ES) | 2025-01-09 | — | — | WO | disclosed |
| WO-2025008381-A1 | SUBSTITUTED HEXAHYDRO-2H-PYRAZINO[1,2-A]PYRAZIN-1(6H)-ONE DERIVATIVES AS ACTIVATORS OF HUMAN CASEINOLYTIC PROTEASE P (HSCLPP) | CENTRO ATLÁNTICO DEL MEDICAMENTO, S.A. (CEAMED S.A.) (ES) | 2025-01-09 | — | — | WO | disclosed |
| WO-2025008381-A1 | SUBSTITUTED HEXAHYDRO-2H-PYRAZINO[1,2-A]PYRAZIN-1(6H)-ONE DERIVATIVES AS ACTIVATORS OF HUMAN CASEINOLYTIC PROTEASE P (HSCLPP) | CENTRO ATLÁNTICO DEL MEDICAMENTO, S.A. (CEAMED S.A.) (ES) | 2025-01-09 | — | — | WO | disclosed |
| EP-4488279-A1 | SUBSTITUTED HEXAHYDRO-2H-PYRAZINO[1,2-A]PYRAZIN-1(6H)-ONE DERIVATIVES AS ACTIVATORS OF HUMAN CASEINOLYTIC PROTEASE P (HSCLPP) | Centro Atlantico del Medicamento S.A (Ceamed, S.A) (ES) | 2025-01-08 | — | — | EP | disclosed |
| EP-4488279-A1 | SUBSTITUTED HEXAHYDRO-2H-PYRAZINO[1,2-A]PYRAZIN-1(6H)-ONE DERIVATIVES AS ACTIVATORS OF HUMAN CASEINOLYTIC PROTEASE P (HSCLPP) | Centro Atlantico del Medicamento S.A (Ceamed, S.A) (ES) | 2025-01-08 | — | — | EP | disclosed |
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | GLAXOSMITHKLINE LLC (US) | 2010-06-17 | — | — | US | disclosed |
| US-7683056-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683056-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683056-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2008-10-30 | — | — | US | disclosed |
| EP-1928886-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | SmithKline Beecham Corporation (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007028654-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007028654-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | SLC6A3, NDUFS5, NDUFB6 | ALDH1A1 490/4885KDM4E 1960/4885TAAR1 653/4885 |
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | CHRNA7, NR3C2, CHRNA6 | ALDH1A1 1956/4885KDM4E 4100/4885TAAR1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.